The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2021 | Recent trials of KRAS targeting and the future
Colin Lindsay, BSc, MBChB, MRCP, PhD, Christie NHS Foundation Trust, Manchester, UK, comments on recent trials for lung cancer treatment, highlighting investigation of G12C inhibitors for KRAS-mutant lung cancer and the possibility of G12C inhibitors being used in combination with immune checkpoint inhibitors in the future. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.
Disclosures
Colin Lindsay, BSc, MBChB, MRCP, PhD, has participated in an advisory role for Amgen and cbpartners; has participated in clinical trials with Amgen, Apollomics, BI, Mirati Therapeutics, Revolution Medicines and Roche; and has participated in a review paper coordinated by Amgen.
